Table 3. Evolution of PCR parameters, cardiac conditions and serology among studies on benznidazole treatment for 30 and 60 days.

Study	Events	Total	Proportion 95% CI
Time of treatment: 60 days
Andrade et al.12	8	13	0.62 [0.32; 0.86]
Andrade et al.13	16	21	0.76 [0.53; 0.92]
Oliveira et al.16	16	21	0.76 [0.53; 0.92]
Pérez-Antón et al.19	38	38	1.0 [0.91; 1.00]
Pinazo et al.29	55	56	0.98 [0.90; 1.00]
Vallejo et al.33	7	7	1.0 [0.50; 1.00]
Subtotal (95% CI)		156	0.93 [0.71; 0.99]
Total Events	140
Heterogeneity: I2 = 84%, π2 = 2.8331, p = 0.09
Time of treatment: 30 days
Coura et al.22	26	26	1.00 [0.87; 1.00]
Viotti et al.31	268	283	0.95 [0.91; 0.97]
Viotti et al.32	53	53	1.00 [0.93; 1.00]
Subtotal (95% CI)		362	0.99 [0.69; 1.00]
Total Events	347
Heterogeneity: I2 = 60%, π2 = 1.6063, p = 1.00
Total (95% CI)		518	0.97 [0.84; 0.99]
Total Events	487
Heterogeneity: I2 = 90%, π2 = 3.8301, p < 0.01
Residual heterogeneity: I2 = 25%, p = 0.23